Powell, Matthew A.; Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA
Bjørge, Line; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway ; Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway
Willmott, Lyndsay; Department of Gynecologic Oncology, Arizona Center for Cancer Care, Phoenix, AZ, USA
Novák, Zoltán ; Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary
Black, Destin; Division of Gynecologic Oncology, Willis-Knighton Cancer Center, Willis-Knighton Health System, Gynecologic Oncology Associates, Shreveport, LA, USA
Gilbert, Lucy; Division of Gynecologic Oncology, Research Unit, McGill University Health Centre, Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
Sharma, Sudarshan; Department of Obstetrics/Gynecology, AMITA Health Adventist Medical Center, Hinsdale, IL, USA
Valabrega, Giorgio; Department of Oncology, University of Turin, Turin, Italy ; Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy
Landrum, Lisa M.; Department of Obstetrics and Gynecology, Indiana University Health and Simon Cancer Center, Indianapolis, IN, USA
Gropp-Meier, Martina; AGO Study Group, Wiesbaden, Germany ; Department of Gynaecological Oncology, Oberschwabenklinik, St. Elisabethen-Klinikum, Ravensburg, Germany
Stuckey, Ashley; Department of Women’s Oncology, Women and Infants Hospital of Rhode Island, Providence, RI, USA
Boere, Ingrid; Department of Medical Oncology, Erasmus MC Cancer Centre, Rotterdam, Netherlands
Gold, Michael A.; Department of Gynecologic Oncology, Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, USA
Segev, Yakir; Department of Obstetrics and Gynaecology, Carmel Medical Center, Technion-Israel Institute of Technology, Haifa, Israel
Gill, Sarah E.; Department of Gynecologic Oncology, St Joseph’s/Candler Gynecologic Oncology and Surgical Specialists, Candler Hospital, Savannah, GA, USA
Gennigens, Christine ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Sebastianelli, Alexandra; Department of Obstetrics, Gynecology, and Reproduction, CHU de Québec-Université Laval, Quebec, QC, Canada
Shahin, Mark S.; Department of Gynecologic Oncology, Hanjani Institute for Gynecologic Oncology, Abington Hospital–Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College of Thomas Jefferson University, Willow Grove, PA, USA
Pothuri, Bhavana; Departments of Obstetrics/Gynecology and Medicine, Division of Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA ; GOG Foundation, Philadelphia, PA, USA
Monk, Bradley J.; GOG Foundation, Philadelphia, PA, USA ; Division of Gynecologic Oncology, Gynecologic Oncology, Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA
Buscema, Joseph; Gynecologic Oncology, Arizona Oncology, Tucson, AZ, USA
Coleman, Robert L.; Department of Gynecologic Oncology, Texas Oncology, US Oncology Network, The Woodlands, TX, USA
Slomovitz, Brian M.; Department of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, FL, USA ; Department of Obstetrics and Gynecology, Florida International University, Miami Beach, FL, USA
Ring, Kari L.; University of Virginia Health System, Department of Gynecologic Oncology, Charlottesville, VA, USA
Herzog, Thomas J.; University of Cincinnati Cancer Center, Department of Obstetrics and Gynecology, College of Medicine, Cincinnati, OH, USA
Balas, Morad Marco; GSK, New York, NY, USA
Grimshaw, Matthew; GSK, London, UK
Stevens, Shadi; GSK, London, UK
Lai, Dominic W.; GSK, Los Angeles, CA, USA
McCourt, Carolyn; Division of Gynecologic Oncology, Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA
Mirza, Mansoor Raza; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark ; Nordic Society of Gynaecologic Oncology–Clinical Trial Unit, Copenhagen, Denmark
Matthew A. Powell reports consulting fees from AstraZeneca, Clovis Oncology, Eisai, GSK/Tesaro, MSD, and Seagen/Pfizer. Line Bjørge reports consulting fees from GSK for a European advisory board; honoraria from MSD; payment for expert testimony from Onsagers; leader of Onkologisk Forum, president of NSGO, leader of the NSGO-CTU foundation; faculty member for the Gynaecological Cancers group in ESMO; and drug support for a researcher-initiated trial from AstraZeneca. Lyndsay Willmott reports speakers’ bureau fees from AstraZeneca, Eisai, ImmunoGen/AbbVie, MSD, and Seagen/Pfizer; and advisory board fees from AstraZeneca, ImmunoGen/AbbVie, and Seagen/Pfizer. Zoltán Novák reports honoraria from AstraZeneca, MSD, and Sofmedica; support for attending meetings from PregLem and Sofmedica; participation on a data safety monitoring board or advisory board for AstraZeneca and Richter Gedeon; stock options from Richter Gedeon; receipt of equipment, materials, drugs, medical writing, gifts, or other services from AstraZeneca; and presidency of the Hungarian Society of Gynecological Oncology. Destin Black reports institutional grant fees from GSK, fees for being a member of GOG Partners Investigational Council, and medical director/owner of Trials365, LLC. Lucy Gilbert reports institutional grants from Alkermes, Ascendis Pharma, AstraZeneca, Corcept Therapeutics, Daiichi Sankyo, Espersas, GOG Foundation, GSK, ImmunoGen, IMV Technologies, K-Group Beta/Zentalis Pharmaceuticals, Mersana Therapeutics, MSD, MSK Pharmalogistic, Novocure, OncoQuest Pharmaceuticals, Pfizer, Roche, Shattuck Labs, Sutro Biopharma, Tesaro/GSK, and Seagen/Pfizer; consulting fees from MSD, GSK, and Repare Therapeutics; honoraria from GSK; travel support from GOG Foundation, GSK, MSD, and Zentalis Pharmaceuticals; and participation in advisory board meetings for CanariaBio, Corcept Therapeutics, Eisai, GSK, ImmunoGen/AbbVie, Kora Healthcare, and MSD. Giorgio Valabrega reports consulting fees from GSK; honoraria from AstraZeneca, GSK, and MSD; travel support from AstraZeneca and PharmaMar; and participation on a data safety monitoring board or advisory board for AstraZeneca, Eisai, GSK, and MSD. Lisa M. Landrum reports participation in a scientific advisory board for GSK. Martina Gropp-Meier reports support for attending meetings and/or travel from GSK. Ashley Stuckey reports royalties as an UpToDate reviewer. Ingrid Boere reports participation on an advisory board for AstraZeneca and participation on a data safety monitoring board for Verastem Oncology. Christine Gennigens reports grants/contracts from AstraZeneca, Deciphera, and GSK; consulting fees from GSK, Ipsen, and MSD; honoraria from AstraZeneca, Bristol Myers Squibb, Ipsen, MSD, Pfizer, and PharmaMar; support for attending meetings from AstraZeneca, GSK, Ipsen, MSD, Pfizer, and PharmaMar; and participation on a data safety monitoring or advisory board for AstraZeneca, Bristol Myers Squibb, Eisai, Genmab, GSK, Ipsen, MSD, and pharma&. Alexandra Sebastianelli reports honoraria from Eisai, GSK, Johnson & Johnson, and MSD and participation on a data safety monitoring board or advisory board for Eisai and GSK. Mark S. Shahin reports consulting fees from AstraZeneca, GSK, and MSD; honoraria for lectures, presentations, speakers’ bureaus, or educational events from AstraZeneca, Caris Life Sciences, Eisai, Genmab, GSK, ImmunoGen/AbbVie, MSD, and Myriad Genetics; and board membership for Unite for Her. Bhavana Pothuri reports institutional research support from Acrivon Therapeutics, Agenus, Alkermes, AstraZeneca, Celgene/Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, DualityBio, Eisai, I-Mab Biopharma, ImmunoGen/AbbVie, Imunon, Incyte, Karyopharm Therapeutics, LOXO Oncology/Lilly, Mersana Therapeutics, MSD, NRG Oncology, Onconova Therapeutics/Traws Pharma, Pfizer, Roche/Genentech, Seagen/Pfizer, Sutro Biopharma, Takeda, Tesaro/GSK, Toray Industries, VBL Therapeutics, and Xencor; consulting fees from AstraZeneca, BioNTech, DualityBio, Eisai, GOG Foundation, ImmunoGen/AbbVie, Imunon, Imvax, Incyte, InxMed, Karyopharm Therapeutics, Mersana Therapeutics, Natera, Onconova Therapeutics/Traws Pharma, OnCusp Therapeutics, R Pharm, Regeneron, Seagen/Pfizer, Sutro Biopharma, and Tesaro/GSK; honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Albert Einstein-Montefiore, Aptitude Health, Bio Ascend, Colorado University, Curio, Lankenau Medical Center, OncLive, PeerView, PERS, Vanium Group, and Yale University; travel support from GOG Partners; participation on a data safety monitoring or advisory board for AstraZeneca, BeiGene, BioNTech, Daiichi Sankyo, GOG Foundation, I-Mab Biopharma, Imunon, ImmunoGen/AbbVie, Imvax, InxMed, LOXO Oncology/Lilly, Mersana Therapeutics, MSD, Nuvation Bio, Onconova Therapeutics/Traws Pharma, Sutro Biopharma, Tesaro/GSK, and Toray Industries; membership on the GOG Partners Leadership committee; vice presidency of the NYOB Society; and membership on the SGO board of directors. Bradley J. Monk reports institutional research funding from Advaxis/Ayala Pharmaceuticals, Amgen, Array BioPharma/Pfizer, AstraZeneca, Genentech, ImmunoGen/AbbVie, Lilly, Janssen/Johnson & Johnson Innovative Medicine, Morphotek/Eisai, Novartis, NuCana, Pfizer, Regeneron, and Tesaro/GSK; consulting or advisory fees from AbbVie, Alkermes, AstraZeneca, BioNTech, Corcept Therapeutics, Daiichi Sankyo, Eisai, Genmab/Seagen/Pfizer, GOG Foundation, Gradalis, ImmunoGen/AbbVie, Incyte, Karyopharm Therapeutics, Lilly, Mersana Therapeutics, MSD, Myriad Genetics, Natera, Novartis, Novocure, OncoC4, Panavance Therapeutics, pharma&, ProfoundBio, Regeneron, Roche/Genentech, Sutro Biopharma, Tubulis, Verastem Oncology, Zentalis Pharmaceuticals, and Zymeworks; speakers’ bureau fees from AstraZeneca, Eisai, ImmunoGen/AbbVie, Lilly, MSD, and Tesaro/GSK; and honoraria from AbbVie, AstraZeneca, BioNTech, Corcept Therapeutics, Daiichi Sankyo, Eisai, Genmab, Genmab/Seagen/Pfizer, GOG Foundation, GSK, ImmunoGen/AbbVie, Incyte, Karyopharm Therapeutics, Lilly, Mersana Therapeutics, MSD, Mural Oncology, Myriad Genetics, Natera, Novartis, Novocure, Onco4, Panavance Therapeutics, pharma&, ProfoundBio, Regeneron, Roche/Genentech, Sutro Biopharma, Tubulis, Verastem Oncology, Zentalis Pharmaceuticals, and Zymeworks. Joseph Buscema reports payment for participation on an advisory board from GSK. Robert L. Coleman reports grants or contracts from AstraZeneca, Clovis Oncology, Genelux, Genmab, ImmunoGen, Merck, and Roche/Genentech; consulting fees from AbbVie, Agenus, Alkermes, AstraZeneca, Clovis Oncology, Deciphera, Genelux, Genmab, GSK, ImmunoGen, Novocure, Merck, OncoQuest, OncXerna, Regeneron, and Roche/Genentech; honoraria from AstraZeneca, Clovis Oncology, Merck, and Roche/Genentech; and participation on a data safety monitoring board or advisory board for Eisai/Bristol Myers Squibb and VBL Therapeutics. Brian M. Slomovitz reports consulting fees from Aadi Bioscience, AstraZeneca, BioNTech, Clovis Oncology, Eisai, Genentech, Genmab, Gilead Sciences, GSK, Incyte, Karyopharm Therapeutics, MSD, Novartis, Novocure, Regeneron, and Seagen/Pfizer and payment or honoraria from Seagen/Pfizer. Thomas J. Herzog reports consulting fees from Aadi Bioscience, AbbVie, AstraZeneca, Caris Life Sciences, Clovis Oncology, Corcept Therapeutics, Eisai, Epsilogen, Genmab, GSK, MSD, Pfizer, and Roche/Genentech; participation on a data safety monitoring board for Corcept Therapeutics; and a leadership role in the GOG Foundation. Mansoor Raza Mirza reports advisory board fees from AbbVie, Allarity Therapeutics, AstraZeneca, BIOCAD, BioNTech, Daiichi Sankyo, Eisai, Genmab, GSK, ImmunoGen/AbbVie, Incyte, Karyopharm Therapeutics, MSD, Regeneron, and Zai Lab; honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from AstraZeneca, Eisai, GSK, Takeda, and Zai Lab; support for meetings or travel from AstraZeneca and GSK; board of director roles at Karyopharm Therapeutics and Sera Prognostics; and stock options from Karyopharm Therapeutics and Sera Prognostics. Michael A. Gold, Sarah E. Gill, Carolyn McCourt, Kari L. Ring, Sudarshan Sharma, and Yakir Segev have nothing to disclose. Morad Marco Balas, Matthew Grimshaw, Dominic W. Lai, and Shadi Stevens are employed by GSK and hold financial equities in GSK.
GSK is committed to sharing anonymized subject-level data from interventional trials as per GSK policies and as applicable. Requests for subject-level data should be done via the GSK link: https://www.gsk-studyregister.com/en/.
